AlphAIAlphAI — Financial news for AI agents
tipranks.comSEP 91 min read$KZIA

Kazia Therapeutics announces first patient dosed in PNOC035 study - TipRanks.com

Kazia Therapeutics (KZIA) dosed the first patient in a Phase 2 study of paxalisib combined with gemcitabine for pediatric brain cancer. The trial, conducted by the Pediatric Neuro-Oncology Consortium, follows preclinical data showing increased survival rates. Paxalisib has FDA designations for this indication.

Original reporting
tipranks.com
Published Sep 9, 2026, 6:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 7:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$KZIA
Bullish
medium confidence
Mentioned
$KZIA
Relevance
8/10
AlphAI data visualization · based on tipranks.com
Decision brief

The 30-second read

$KZIABullishLow
01

Why it matters

The first patient dosing marks a transition from preclinical to clinical validation, a key milestone for biotech investors.

02

Market read

Trial initiation may trigger short‑term buying pressure in KZIA, while broader market impact remains limited.

03

What to watch

Potential regulatory hurdles and the need for robust survival data could delay commercialization.

Relevance 8/10Novelty 8/10Timing: Sep 9 2026 announcement

Background

Kazia Therapeutics (NASDAQ:KZIA) focuses on pediatric oncology; paxalisib has orphan and rare disease designations.

Company-level read

Ticker impact

$KZIABullishMedium confidence
Context

Kazia Therapeutics announced the first patient dosed in the Phase 2 PNOC035 study of paxalisib plus gemcitabine.

Expected impact

Potential short‑term upside as investors price in early clinical data expectations.

Evidence & confidence

Early trial enrollment is a material catalyst for a micro‑cap biotech, but actual efficacy data are still pending.

Market effects

Sector

Advances in pediatric brain‑cancer therapies could benefit other biotech firms developing paxalisib or similar agents.

Regional

Limited to U.S. biotech sector; no broader regional effect.

Global

Modest, as the trial targets a rare pediatric cancer with niche investor interest.

Counterpoint

What could challenge this read

Early dosing does not guarantee efficacy; the stock may be over‑priced on speculative hope.

Key entities

  • Company
    Kazia Therapeutics

    Biotech developing paxalisib for pediatric brain tumors.

  • Organization
    Pediatric Neuro‑Oncology Consortium (PNOC)

    Runs the multi‑center PNOC035 platform trial.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 22
$KZIAMedAI 8/10

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Kazia Therapeutics (KZIA) announced that Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders. The milestone triggers a $2 million payment to Kazia, with potential for up to $17 million more. Paxalisib is being developed for intractable epilepsy associated with FCD T2 and TSC, with Kazia retaining oncology focus.

prnewswire.com2 min
SEP 9
$KZIALowAI 8/10

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia Therapeutics (NASDAQ: KZIA) announced the first patient has been dosed in a Phase 2 study (PNOC035) evaluating paxalisib plus gemcitabine for recurrent pediatric AT/RT brain cancer. The study, conducted by the Pediatric Neuro-Oncology Consortium, aims to address a condition with no approved therapies. Preclinical data showed a significant survival increase, supporting the trial's rationale. Paxalisib has received FDA orphan drug and rare pediatric disease designations for AT/RT.

prnewswire.com2 min
SEP 1
$KZIAMedAI 8/10

Kazia Reports Paxalisib Data In Immunotherapy-Resistant Colorectal Cancer

Kazia Therapeutics (KZIA) reported preclinical data showing its lead asset, paxalisib, reduced tumor burden in immunotherapy-resistant colorectal cancer by 52% as a monotherapy and by an additional 50% when combined with Pembrolizumab. The treatment was well tolerated, and the company plans to advance paxalisib into a Phase 2 clinical study. KZIA's stock closed at $13.77, up 1.40%, and was at $13.90 in pre-market trading.

rttnews.com2 min
SEP 1
$KZIALow

Kazia advances paxalisib colorectal cancer program

Kazia Therapeutics (KZIA) reported paxalisib reduced tumor burden by 52% in a colorectal cancer model. The company plans a Phase 2 trial in 2027, evaluating paxalisib alone and with immunotherapy. Kazia is developing biomarkers and has filed a patent for colorectal cancer applications.

grafa.com1 min
SEP 1
$KZIAMedAI 8/10

Kazia expands paxalisib breast cancer trial program

Kazia Therapeutics reported preclinical data showing paxalisib's activity in HR+/HER2- breast cancer models. The company will expand its clinical trial to evaluate paxalisib combinations in metastatic breast cancer, with patient enrollment expected to begin before the end of 2026. Kazia filed a provisional patent related to the program and expects full enrollment by the end of 2027, with a complete data readout in 2028.

grafa.com1 min
SEP 1
$KZIAMedAI 8/10

BTIG raises Kazia Therapeutics stock price target on trial data

BTIG raised its price target for Kazia Therapeutics (NASDAQ:KZIA) to $40 from $34, citing positive trial data for paxalisib in metastatic triple-negative breast cancer. The stock has surged nearly 100% year-to-date to $12.71. Kazia also announced a $40 million public offering. BTIG noted the data showed an 83% overall response rate and no serious adverse events.

investing.com2 min